Home/Filings/4/0001193125-25-241634
4//SEC Filing

BridgeBio Pharma, Inc. 4

Accession 0001193125-25-241634

$BBIOCIK 0001869105operating

Filed

Oct 15, 8:00 PM ET

Accepted

Oct 16, 5:54 PM ET

Size

8.2 KB

Accession

0001193125-25-241634

Insider Transaction Report

Form 4
Period: 2025-10-10
Transactions
  • Other

    Common Stock

    2025-10-10+784,72014,589,846 total
Transactions
  • Other

    Common Stock

    2025-10-10+784,72014,589,846 total
Footnotes (3)
  • [F1]Shares issued pursuant to an amendment to the Transition Services Agreement dated August 11, 2025 in exchange for additional financial and accounting support services provided through December 31, 2025.
  • [F2]Shares are held by BridgeBio Pharma LLC ("BBIO LLC"). Voting and investment power over the shares held by BBIO LLC is exercised by its parent entity, BridgeBio Pharma, Inc. ("BBIO"). The board of directors of BBIO consists of Neil Kumar, Ph.D., Eric Aguiar, M.D., Jennifer E. Cook, Douglas A. Dachille, Ronald J. Daniels, Andrea J. Ellis, Fred Hassan, Charles Homcy, M.D., Andrew W. Lo, Ph.D., Frank P. McCormick, Ph.D., F.R.S., D.Sc., James C. Momtazee, Ali J. Satvat, Randal W. Scott, Ph.D., and Hannah A. Valantine, M.D. (each a BBIO director, and collectively, the "BBIO Directors"). None of the members of the board of directors of BBIO or BBIO LLC has individual voting or investment power with respect to such shares. Each of BBIO and the BBIO Directors disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its, his, or her pecuniary interest therein, if any.
  • [F3](Continued from Footnote 2) This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Documents

1 file

Issuer

BridgeBio Oncology Therapeutics, Inc.

CIK 0001869105

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001743881

Filing Metadata

Form type
4
Filed
Oct 15, 8:00 PM ET
Accepted
Oct 16, 5:54 PM ET
Size
8.2 KB